Pillar Biosciences seeks to make precision medicine a first-line therapy for cancer patients
Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics, in response to emailed questions from MedCity News. Why did you join Pillar Biosciences? I am incredibly impressed with the technology and the amazing team at Pillar that have done so much work to bring our oncoReveal™ Dx […]